Browse CEBPG

Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF07716 Basic region leucine zipper
Function

Transcription factor that binds to the promoter and the enhancer regions of target genes. Binds to the enhancer element PRE-I (positive regulatory element-I) of the IL-4 gene (PubMed:7665092). Binds to the promoter and the enhancer of the immunoglobulin heavy chain. Binds to GPE1, a cis-acting element in the G-CSF gene promoter.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0001889 liver development
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002262 myeloid cell homeostasis
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002521 leukocyte differentiation
GO:0006282 regulation of DNA repair
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030183 B cell differentiation
GO:0030218 erythrocyte differentiation
GO:0032609 interferon-gamma production
GO:0032649 regulation of interferon-gamma production
GO:0032729 positive regulation of interferon-gamma production
GO:0034101 erythrocyte homeostasis
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042095 interferon-gamma biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042113 B cell activation
GO:0042267 natural killer cell mediated cytotoxicity
GO:0043353 enucleate erythrocyte differentiation
GO:0043388 positive regulation of DNA binding
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0045072 regulation of interferon-gamma biosynthetic process
GO:0045078 positive regulation of interferon-gamma biosynthetic process
GO:0045739 positive regulation of DNA repair
GO:0048732 gland development
GO:0048872 homeostasis of number of cells
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051101 regulation of DNA binding
GO:0061008 hepaticobiliary system development
GO:2001020 regulation of response to DNA damage stimulus
GO:2001022 positive regulation of response to DNA damage stimulus
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0008134 transcription factor binding
GO:0008301 DNA binding, bending
GO:0044374 sequence-specific DNA binding, bending
GO:0044377 RNA polymerase II core promoter proximal region sequence-specific DNA binding, bending
GO:0046982 protein heterodimerization activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CEBPG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CEBPG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 4.04; FDR: 0.017 Resistant to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 4.59; FDR: 0.008 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CEBPG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1170.562
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5820.728
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2260.847
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.030.951
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4490.726
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5070.771
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0730.835
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.180.907
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0230.989
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5350.632
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2250.451
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.260.00336
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CEBPG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CEBPG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CEBPG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CEBPG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CEBPG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CEBPG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CEBPG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCEBPG
NameCCAAT/enhancer binding protein (C/EBP), gamma
Aliases GPE1BP; IG/EBP-1; c/EBP gamma; CCAAT/enhancer-binding protein gamma
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CEBPG collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.